CIN2 and Active Surveillance: Evidence from 48-Month Follow-Up in an HPV-Positive Cohort
Active surveillance for CIN2 remains a valid strategy in low-risk subgroups, but it is not universally safe. Data suggest that the combination of high-grade cytology and HPV 16/18 represents a high oncological risk profile, for which prompt treatment is indicated. Persistence beyond 36 months should be considered a cumulative risk marker, with implications for personalized follow-up and risk management. Further prospective, registry-linked studies are required to validate long-term safety and refine risk-based management strategies for CIN2.
Authors
- Maria Teresa Bruno (ORCID: https://orcid.org/0000-0003-1557-1538)
- Gaetano Valenti (ORCID: https://orcid.org/0000-0003-4756-587X)
- Giorgia Campo (ORCID: https://orcid.org/0000-0001-6439-1459)
- Zaira Ruggeri
- M Somma
- Antonino Giovanni Cavallaro
- A. Fiorito
- Alessia Pagana (ORCID: https://orcid.org/0009-0009-9690-8198)
- Roberta Siena (ORCID: https://orcid.org/0009-0002-6044-1273)
Institutions
- University of Messina (IT)
- Humanitas University (IT)
- Magna Graecia University (IT)
- University of Catania (IT)
- Regione Siciliana (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3390/cancers17233796
- Citations
- 2
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 2.71